[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behcet-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behcet-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,83,119,141,169,201,237,270],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644378","behcet-disease-patients-with-pulmonary-endoarterectomy-outcomes-of-program-of-inspiratory-msucle-trianing-100644378",false,"NCT07662603","Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing","Inclusion Criteria:\n\n* adlescent patients\n* complain Behcet disease\n* after pulmonary endoarterectomy\n\nExclusion Criteria:\n\n* chronci cardiac diseases\n* psychic disease\n* mental disease","ALL","13 Years","17 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated",[26],"Behcet Disease","RECRUITING","2026-06-17",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":31},"2026-05-06",{"date":35,"type":20},"2026-09-06",{"name":37,"class":38},"Cairo University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":65,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":39},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885","NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","18 Years",{"count":49,"type":20},5000,"OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[53,54,55,56,57,58,59,60,26,61,62,63,64],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[66,67,68,69,70,71,72,73],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","2026-06-03",{"date":76,"type":31},"2026-06-05",{"date":78,"type":31},"2025-11-19",{"date":80,"type":20},"2028-10-30",{"name":82,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":15,"minAge":47,"maxAge":90,"enrollmentInfo":91,"targetDuration":92,"studyType":50,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":39},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).",true,"99 Years",{"count":49,"type":20},"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[95,96,97,98,99,100,57,26,101,102,103,104,105,106,59,62,56,107,108,109],"Rheumatic Diseases","Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":112,"type":31},"2026-02-13",{"date":114,"type":31},"2020-08-04",{"date":116,"type":20},"2030-06-01",{"name":118,"class":38},"Yale University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":89,"sex":15,"minAge":47,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":39},"100603326","cranial-nerve-functions-in-behets-disease-and-their-relationship-with-clinical-parameters-100603326","NCT07135063","Cranial Nerve Functions in Behçet's Disease and Their Relationship With Clinical Parameters","Inclusion Criteria:\n\n* Aged 18-75\n* Diagnosed with BD according to ACR\u002FEULAR 2013 criteria (patient group)\n* Healthy with no relevant medical history (control group)\n\nExclusion Criteria:\n\n* Conditions affecting CN assessment (e.g., facial trauma, surgery, radiotherapy)\n* Other rheumatologic or autoimmune diseases\n* Psychiatric disorders, alcohol\u002Fsubstance abuse\n* Pregnant women\n* Use of pacemakers or recent botox to masseter muscle","75 Years",{"count":127,"type":20},60,"The goal of this study is to find out whether cranial nerves are affected in people with Behçet's Disease (BD), and how this might relate to other disease features. Cranial nerves control important functions such as vision, facial movement, hearing, swallowing, and balance.\n\nThe main questions this study will address are:\n\n* Do people with BD have changes in cranial nerve function compared to healthy individuals?\n* Are these changes linked to disease duration, symptoms, or lab results?\n\nParticipants will:\n\n* Answer questions about their medical history and BD symptoms\n* Complete questionnaires on daily function, mood, and autonomic symptoms\n* Have a clinical examination of all 12 cranial nerves\n* Undergo non-invasive electrical tests to assess nerve function This study will not involve any medications. All procedures will be completed in one visit.",[26,130],"Cranial Nerve Disorder","NOT_YET_RECRUITING","2025-08-13",{"date":134,"type":31},"2025-08-21",{"date":136,"type":20},"2025-10",{"date":138,"type":20},"2026-09",{"name":140,"class":38},"Marmara University",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":89,"sex":15,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":39},"100597996","quantification--classification-of-inflammatory-cells-in-uveitis-using-oct-100597996","NCT07065747","Quantification & Classification of Inflammatory Cells in Uveitis Using OCT","Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis\u002FHLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.\n2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).\n3. Healthy\u002FControl Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.\n\nExclusion Criteria:\n\n1. Inability to give informed consent.\n2. Inability to maintain stable fixation for OCT imaging.\n3. Inability to commit to required visits to complete the study.\n4. Pregnancy and breastfeeding.","5 Years","85 Years",{"count":151,"type":20},125,"The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.",[154,155,26,156,157,158,62,159],"Anterior Uveitis (AU)","Birdshot Chorioretinitis","Herpes Simplex Virus","Juvenile Idiopathic Arthritis (JIA)","Spondyloarthritis (SA)","Posterior Vitreous Detachment","2025-07-14",{"date":162,"type":31},"2025-07-17",{"date":164,"type":31},"2024-09-01",{"date":166,"type":20},"2026-12",{"name":168,"class":38},"Oregon Health and Science University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},"100587231","phase-3-immunosuppressive-therapy-alone-versus-plus-oral-anticoagulation-in-the-treatment-of-vt-associated-with-behcets-disease-100587231","NCT06925698","Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease","BETTER","Inclusion Criteria:\n\n* Participants must meet the following criteria to be eligible for the study:\n\nAge between 18-50 years old. Diagnosed with Behçet's Disease according to the International Study Group (ISG) criteria.\n\nNo prior vascular involvement or no previous immunosuppressive therapy for vascular involvement.\n\nConfirmed venous thrombosis in the lower extremity within the last 14 days before randomization.\n\nVenous thrombosis diagnosis confirmed by:\n\nNon-compressible venous segment in ultrasound, OR A significant (\\>4 mm) increase in thrombus diameter in an already abnormal segment, OR New intraluminal filling defect on venography, CT, or MR angiography.\n\nFemale participants must:\n\nNot be pregnant or breastfeeding. Use effective contraception if of childbearing potential. Be postmenopausal (no menses for at least 1 year) or have undergone surgical sterilization.\n\nAbility to provide written informed consent and comply with study requirements.\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following criteria:\n\nPresence of any aneurysm. Chronic multisystemic disease other than Behçet's Disease. History of intolerance to Rivaroxaban. Use of immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, or interferon-gamma) within the last 6 months.\n\nProlonged corticosteroid use (\\>3 months) for Behçet's Disease mucocutaneous symptoms.\n\nPrior anticoagulant therapy:\n\nLow molecular weight heparin, fondaparinux, or unfractionated heparin for \\>48 hours before randomization.\n\nMore than one dose of vitamin K antagonists before randomization. Thrombectomy, vena cava filter placement, or fibrinolytic therapy for the current thrombotic episode.\n\nPlanned administration of a live vaccine within 30 days after randomization. Clinically significant acute or uncontrolled chronic diseases (e.g., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) that may interfere with study results.\n\nPlanned surgical procedure or significant medical condition deemed unsuitable for the study by the investigator.\n\nHistory of malignancy within the last 5 years (except adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix).\n\nRenal impairment (Creatinine clearance \\\u003C30 ml\u002Fmin). Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis, or ALT \\>3 times the upper limit).\n\nActive bleeding or high bleeding risk contraindicating anticoagulant therapy. Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg). Severe anemia (Hemoglobin \\\u003C10 mg\u002FdL). Women who are pregnant, breastfeeding, or of childbearing potential without contraception.\n\nUse of strong CYP3A4 inhibitors or inducers (e.g., protease inhibitors, systemic ketoconazole, rifampin, carbamazepine, phenytoin).\n\nParticipation in another experimental drug study within the last 30 days. Life expectancy of less than 3 months. History of serious infections within the last 60 days (e.g., bacterial endocarditis, tuberculosis, opportunistic infections).\n\nActive substance or alcohol abuse or history of substance dependence within the last year.\n\nPositive screening for Hepatitis B surface antigen, Hepatitis C antibody, or known HIV-1 infection.\n\nKnown coagulation disorders or laboratory abnormalities (e.g., DMID toxicity scale Grade 3 or higher).\n\nHistory of suicidal behavior in the last 6 months or suicidal ideation (C-SSRS type 4 or 5) in the last 2 months.","50 Years",{"count":179,"type":20},110,[181],"PHASE3","This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).",[26,184,185,186],"Behcet Disease and Vascular Involvement","Deep Venous Thromboses","Post Thrombotic Syndrome",[188,189,190,191],"Behcet's disease","Deep venous thrombosis","Anticoagulant therapy","Rivaroxaban","2025-04-07",{"date":194,"type":31},"2025-04-13",{"date":196,"type":20},"2025-04-30",{"date":198,"type":20},"2028-04-01",{"name":140,"class":38},2,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":236},"100508736","armenian-nationwide-registry-of-systemic-autoimmune-and-autoinflammatory-diseases-100508736","NCT05904301","Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","Armenian Nationwide Registry of Systemic Autoimmune and Autoinflammatory Diseases","NAREG","Inclusion Criteria:\n\n1. Patients with a confirmed diagnosis of at least one of following autoimmune systemic diseases:\n\n   Behcet disease, ANCA -positive vasculitis, Takayasu arteritis, Giant cell arteritis, Systemic sclerosis, Sjogren syndrome, Rheumatoid arthritis, Spondylarthritis (psoriatic, ankylosing, crohn's related), Angioedema hereditary and acquired, Pediatric dermatology, Autoinflammatory diseases (hereditary and acquired), Unexplained infertility, Immune thrombocytopenic purpura\u002F Autoimmune hemolytic anemia (ITP, AHA), Primary anti-phospholipid syndrome (APS), Celiac disease.\n2. Age: major and minor\n3. Patients who have been informed and provided with written informed consent to participate Or consent from legal representative\n\nExclusion Criteria:\n\n1. Patients refusing to participate in the registry\n2. Non-consent from legal representative\n3. Breastfeeding or pregnant patients",{"count":210,"type":20},800,"Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.",[26,213,61,103,108,59,214,215,216],"Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis","Hereditary and Acquired Angioedema","Primary Antiphospholipid Syndrome","Celiac Disease",[218,219,220,221,222,223,224,225,226],"arthritis","autoimmune","systemic","autoinflammatory","Behcet","Takayasu","Giant Cell","Angioedema","APS","2025-04-04",{"date":229,"type":31},"2025-04-08",{"date":231,"type":31},"2023-06-21",{"date":233,"type":20},"2028-06-30",{"name":235,"class":38},"Santé Arménie French-Armenian Research Center",6,{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":249,"conditions":250,"keywords":257,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":39},"100577108","phase-2-bcma-cd19-car-t-therapy-for-refractory-autoimmune-diseases-100577108","NCT06794008","BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases","An Open, Single-Arm, Single-Center Clinical Study Assessing the Safety and Efficacy of BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell Therapy in Multiple Refractory Autoimmune Diseases","Inclusion Criteria:\n\n1. Age, 18-65 years old (inclusive), weight \\>=45kg, male and female;\n2. The diagnosis of each disease meets the following criteria:\n\nSystemic lupus erythematosus: 1997 ACR classification criteria or 2012 SLICC classification criteria Sjögren's syndrome: 2002 International Classification of Sjögren's Syndrome Inflammatory myopathies: 1977 Bohan Recommendation Systemic sclerosis: 1980 ACR classification criteria or 2013 ACR-EULAR classification criteria Behcet's disease: 1989 International Classification Criteria for Behcet's disease ANCA-associated vasculitis: 1990 ACR classification criteria IgG4-related disease: 2011 IgG4-RD composite diagnostic criteria Antiphospholipid syndrome: 2006 revision of the Sapporo APS classification criteria Acquired thrombotic thrombocytopenic purpura: consistent with a clinical diagnosis of TTP, including microscopic evidence of thrombocytopenia and red blood cell fragmentation (e.g., red blood cell fragmentation) 3. Multiple treatment regimens are ineffective or ineffective (including but not limited to high-dose glucocorticoids, adequate immunosuppressants and biologics) 4. Use of glucocorticoids (\\\u003C=1mg\u002Fkg\u002Fd prednisone or equivalent doses of other hormones), DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) must be on stable treatment for 4 weeks before receiving the first study drug, and no increase in hormone dose and other immunosuppressants throughout the study.\n\n5\\. Subjects voluntarily participate in this study and voluntarily sign the informed consent form; 6. Subjects who have the possibility of having children or whose partners have the possibility of having children must agree to use effective contraception throughout the study period (but cannot use oral estrogen, use estrogen vaginal ring, etc.) 7. Additional enrollment criteria for different diseases (related to the degree of disease activity):\n\n1. Patients with Behcet's disease must be active patients who meet the following conditions, and the active phase is defined as the emergence of new symptoms or the deterioration of existing symptoms, and one of the following conditions must be met:\n\n   A. Organ involvement: involvement of any major organ (e.g., ocular lesions, vascular lesions, central nervous system, gastrointestinal system); B. 100% increase in the number of oral or genital ulcers \\>=compared to the onset of oral\u002Fgenital ulcers compared to the first day; or an increase in the number of oral or genital ulcers by 3; C. Canker disease is at least 12 months; D. History of several oral ulcers per month E. Arthritis: \\>=50% increase in the number of swollen joints, or 3 more swollen joints; F. Skin lesions (non-oral\u002Fgenital ulcers): \\>= physician overall lesion score increased by \\>=50% or by two points in the total score.\n2. Patients with active inflammatory myopathy need to meet the following additional conditions:\n\n   Active myositis as defined by the Baseline Freehand Muscle Strength Test (MMT-8) of no more than 125\u002F150 and at least 2 additional CSMs that meet the criteria specified below:\n\n   a) Visual Analogue Scale\\[VAS\\] of patient global activity ≥2 cm, b) physician's global disease activity ≥2 cm, c) Health Assessment Questionnaire (HAQ) Disability Index ≥ 0.25 d) Elevation of at least one muscle enzyme \\[including creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)\\] with a minimum level of 1.3 x upper limit of normal e) Global Extramuscular Disease Activity Score, with a minimum of 1.0 cm on a 10 cm VAS scale \\[This measure is a physician's comprehensive assessment based on the assessment of physique, skin, bone, gastrointestinal, lung, and cardiac activity scale activity scores using the Myositis Disease Activity Assessment Tool (MDAAT).\n\n   f) To ensure that we are able to recruit patients with active DM with severe rash who may not meet the MMT-8 criteria above, we recommend the use of additional inclusion criteria so that the International Myositis Assessment and Clinical Study (IMACS) Improved Definition (DOI) can be achieved: 1) MDAAT \\> on the 10 cm VAS scale 3 cm skin VAS score, and 2) at least 3 of the above 5 criteria.\n3. ANCA-associated vasculitis:\n\n   A. Comply with GPA\u002FMPA\u002FEGPA classification standards; B. Patients with severe vasculitis activity (meeting at least one of the following conditions);\n\n   a) Renal involvement is characterized by one of the following: i. Evidence of glomerulonephritis in any of the following situations: Renal biopsy shows focal necrotizing glomerulonephritis. Active urinary sediment characterized by glomerular hematuria and proteinuria ii. Patients with prior normal or no prior renal disease document, estimated glomerular filtration rate (eGFR) \\\u003C50 ml\u002Fmin\u002F1.73 m2, and prior chronic kidney disease (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2) showed a reduction in eGFR of at least 25% compared with the previous one.\n\n   b) Pulmonary hemorrhage due to active vasculitis satisfies all three of the following: i. Chest X-ray or CT scan showing diffuse pulmonary infiltrates ii. Pulmonary infiltrates that cannot be explained by other causes (e.g., volume overload or pulmonary infection) iii. At least one of the following: Evidence of alveolar hemorrhage on bronchoscopy or bloody bronchoalveolar lavage Hemoptysis was observed Unexplained anemia (\\\u003C10 g\u002FdL) or decreased hemoglobin (\\>1 g\u002FdL) and less than 10g\u002FdL Increased carbon dioxide dispersion\n4. Additional Enrollment Criteria for Systemic Sclerosis:\n\n   Subjects are at high risk of fatal outcomes based on the following prognostic factors: Subjects must have the following \"a\" , and at least one of \"b\" or \"c\".\n\n   a) Diffuse cutaneous scleroderma with an mRSS score of \\>=16, validated by the same physician at 2 different times \\>= 1 day apart and separated by \\\u003C 28 days.\n\n   b) Presence of SSc-related lung disease with FVC \\\u003C 70% or 70% predicted DLCO \\\u003C after hemoglobin correction and evidence of alveolitis obtained by high-resolution chest CT scan or PAL.\n\n   c) History of SSc-related nephropathy, no disease activity before enrollment screening. A history of hypertensive renal crisis with scleroderma is included in this criterion and is defined as follows: i. History of new-onset hypertension based on any of the following (must be repeated and confirmed at least 2 hours apart within 3 days of the first event) with change from baseline SBP\\>=140 mmHg DBP\\>=90 mmHg SBP rose by \\>=30 mmHg compared to baseline DBP increased by \\>=20 mmHg compared to baseline AND ii. One of the following 5 characteristics Serum creatinine increased \\>= \\>50% from baseline proteinuria: \\>=2+; Creatinine ratio \\> upper limit of normal Thrombocytopenia: \\\u003C100, 000 plts\u002Fmm3 Hemolysis: increased by blood smear or reticulocyte count\n5. Additional enrollment criteria for systemic lupus erythematosus A. The SLEDAI score of the patient before enrollment \\>= 7 points B. Failure to receive the following treatments: oral prednisone \\>=20 mg\u002Fd; Cyclophosphamide 0.4 to 0.6 g\u002Fm2 once every two weeks for 6 months, or other immunosuppressants such as mycophenolate mofetil 2 g\u002Fday for 3 months without remission.\n6. Additional enrollment criteria for antiphospholipid syndrome A. Cardiolipin antibody, lupus anticoagulant factor, and anti-β2-glycoprotein 1 antibody were all positive before enrollment.\n\n   B. History of thromboembolism or morbid pregnancy confirmed by clear objective evidence.\n7. Sjögren's disease additional enrollment criteria A. Positive anti-Ro\u002FSSA antibody screen. B. ESSDAI\\>= 6 POINTS\n8. Additional enrollment criteria for IgG4-related diseases (confirmed: A+ B+C) A. Clinical examination showing the presence of characteristic diffuse\u002Flocal swelling or masses in a single or multiple organs.\n\nB. Blood tests show elevated serum IgG4 concentration (135 mg\u002Fdl). C. Histopathological examination shows significant lymphocytic and plasmacytic infiltration and fibrosis or IgG4+ plasmacyte infiltration (IgG4+\u002FIgG+ cell ratio \\>40% and \\>10 IgG4+ plasma cells\u002FHPF).\n\nExclusion Criteria:\n\n1. Use of rituximab or other monoclonal antibodies within 1.6 months.\n2. Received high-dose glucocorticoids (\\>1 mg\u002Fkg\u002Fd) within 1 month.\n3. Serious complications: including heart failure (\\>= NYHA Class III), renal insufficiency (creatinine clearance \\\u003C=30 ml\u002Fmin), hepatic insufficiency (serum ALT or AST greater than three times the upper limit of normal, or total bilirubin greater than the upper limit of normal)\n4. Other severe, progressive, or uncontrollable hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral diseases (including demyelinating diseases such as multiple sclerosis).\n5. Known allergies, hyperreactivity, or intolerance to IL-2 or its excipients.\n6. Have a serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, Epstein-Barr virus, tuberculosis infection), or hospitalization for infection, or use of intravenous antibiotics for treatment of infection 2 months prior to the first dose of treatment.\n7. Chest imaging showing malignancy or current activity within 3 months prior to the first use of study drug Abnormalities in sexually transmitted infections (including tuberculosis).\n8. Infection with HIV (HIV antibody-positive serology) or hepatitis C (Hep C antibody-positive serology).\n\nIf seropositive, it is advisable to consult a physician with expertise in the treatment of HIV or hepatitis C virus infection.\n\n10\\. Any known malignancy or history of malignancy within the past 5 years (with the exception of non-melanoma skin cancer, non-melanoma skin cancer with no signs of recurrence or surgically cured cervical tumor within 3 months prior to the use of the first investigational agent).\n\n11\\. Have an uncontrolled mental or emotional disorder, including a history of drug and alcohol abuse within the past 3 years, which may preclude the successful completion of the study.\n\n12\\. Received or anticipated receipt of any live viral or bacterial vaccine injection within 3 months prior to the first injection of study dose, during the study, or within 4 months after the last injection of study dose. Bacillus Calmette-Guérin vaccination within 12 months of screening.\n\n13\\. Pregnant, lactating women (WCBP) who are unwilling to use medically approved contraception during treatment and for 12 months after the end of treatment.\n\n14\\. Males whose partner is of childbearing potential but who are unwilling to use appropriate medically approved contraception during treatment and for 12 months after the end of treatment.\n\n15\\. Patients with inflammatory myopathies should additionally exclude: 3) Adolescent DM or PM, myositis overlaps with another connective tissue disease, cancer-associated myositis, inclusion body myositis, or any other non-immune-mediated myopathy.\n\n4\\) Severe muscle impairment is defined as a baseline global muscle impairment score of MDI (Myositis Injury Index) \\>=5cm on 10 cm VAS.\n\n16\\. ANCA-associated vasculitis requires additional exceptions: positive anti-GBM antibodies.","65 Years",{"count":246,"type":20},50,[248],"PHASE2","The objective of this study is to evaluate the efficacy and safety of BCMA\u002FCD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.",[57,251,252,253,254,100,255,26,256],"Inflammatory Myopathy","Systemic Sclerosis (SSc)","ANCA-associated Vasculitis","IgG4-Related Diseases","Acquired Thrombotic Thrombocytopenic Purpura","Sjogren Syndrome",[258,259,260],"CAR-T","CD19","BCMA","2025-04-01",{"date":263,"type":31},"2025-04-02",{"date":265,"type":31},"2024-12-26",{"date":267,"type":20},"2027-12-31",{"name":269,"class":38},"Peking University People's Hospital",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":89,"sex":15,"minAge":92,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100580401","evaluation-of-voice-in-behcets-100580401","NCT06836817","Evaluation of Voice in Behcet's","Voice and Behcet's Disease","Inclusion Criteria:\n\n* The inclusion criteria for selection of Group I participants will based on the criteria of the International Study Group which was proposed in 1990. The inclusion criteria for Group II will not have a Behcet's Disease.\n\nExclusion Criteria:\n\n* other autoimmune diseases.",{"count":127,"type":20},"Behçet's disease (BD) is a systemic inflammatory condition of unknown origin with no definite aetiopathogenetic pathways accepted worldwide. To date, only a few studies have investigated laryngeal involvement in BD and data about this are scarce. For these reasons, the present study focuses on verifying the occurrence of vocal cord involvement in patients with BD, identifying potential correlations with specific demographic, clinical, and therapeutic characteristics.",[26],"2025-02-15",{"date":282,"type":31},"2025-02-20",{"date":280,"type":20},{"date":285,"type":20},"2025-06",{"name":287,"class":38},"Minia University"]